CDKN2A and neoplasm: In a previous study using in vitro and in vivo models of primary and secondary GBM, functional p53-activating signals such as CDKN2A (p14ARF) were shown to be required for restoring p53 tumor-suppressor activities following treatment with PRIMA-1 [76].